Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

17%

Ph phase_4

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

4(80.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Other(1)

Detailed Status

Completed5

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (20.0%)

Phase 44 (80.0%)

Trials by Status

completed583%

unknown117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_3

Thrombolysis of Urokinase for Minor Stroke

NCT04420351

completedphase_4

TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI

NCT02018055

unknown

Clinical Trials (6)

Showing 6 of 6 trials

NCT04420351Phase 3

Thrombolysis of Urokinase for Minor Stroke

Completed

NCT02018055Phase 4

TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI

Completed

NCT04654026

the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA

Unknown

NCT00590174Phase 4

Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation

Completed

NCT01186146Phase 4

Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)

Completed

NCT00484926Phase 4

Association of Clopidogrel Therapy and Stent Thrombosis

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6